Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Current options for first-line treatment of metastatic renal cell cancer (mRCC) include agents targeting the vascular endothelial growth factor (VEGF) signalling pathway sunitinib, pazopanib, and bevacizumab (administered in combination with interferon) as well as inhibitor of mammalian target of rapamycin (mTOR) temsirolimus. The standard second-line treatment options are even wider and include mTOR inhibitor (mTORi) everolimus, VEGF inhibitor (VEGFi) axitinib and three new drugs introduced to the clinical practice in 2016, nivolumab, cabozantinib, and lenvatinib. VEGF pathway inhibitors such as sunitinib, sorafenib, or pazopanib may be considered as options for second-line treatment in specific cases [1].

The use of everolimus and axitinib is based on prospective randomized phase III trials: Everolimus was shown to prolong progression-free survival (PFS) compared to placebo in second and higher lines of systemic therapy of mRCC patients, but the overall survival (OS) was not significantly extended, probably due to cross-over from placebo to everolimus arm [2]. Axitinib was also demonstrated to prolong PFS compared to sorafenib, but, again, OS prolongation compared to sorafenib was not statistically significant [3].

It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life patients [4]. Moreover, three more therapeutic options have emerged very recently in the second line therapy of mRCC, including cabozantinib, nivolumab and lenvatinib. In face of such many available treatment options, it is important to re-evaluate the results obtained with currently available drugs in this setting.

The objective of the present retrospective, registry-based study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for mRCC.

The present study documents similar survival achieved with different second-line options for mRCC in the real clinical practice. It also shows declining prescription rates for sorafenib as a second-line option and gradual adoption of the VEGFi-VEGFi strategy as opposed to VEGFi-mTOR strategy in the last years.

The outcomes of patients from the national RENIS registry are comparable with the efficacy data reported from the prospective second-line trials in patients with mRCC. A correlation between the duration of PFS on first-line therapy and second-line treatment was observed in patients treated with second-line everolimus.

The present retrospective study was primarily descriptive, and no conclusions regarding the relative efficacy of the second-line agents can be inferred from these results. Obviously, such data can be obtained only in prospective randomized studies.

Everolimus, sorafenib and sunitinib have previously been studied in prospective trials. In the RECORD-1 study, patients pre-treated with one line of anti-VEGF therapy had PFS of 5.4 months on everolimus [2]. Median PFS for second-line everolimus in the CHANGE study was 6.9 months [12]. These results correspond to those of in RENIS database (6.3 months).

Efficacy of second-line sorafenib and sunitinib in mRCC patients was studied in the prospective, randomised SWITCH trial that compared sunitinib-sorafenib and sorafenib-sunitinib sequences. Median total PFS was 14.9 months in the sunitinib-sorafenib arm and 12.5 months in the sorafenib-sunitinib arm; median PFS of second-line treatment was 2.8 months for sunitinib and 5.4 months for sorafenib [13]. Similar findings from a retrospective study were published earlier by our group based on the RENIS registry [7]. Median PFS for sorafenib in a randomised prospective AXIS study comparing second-line sorafenib with axitinib was 3.4 months compared to 4.8 months for axitinib in patients after previous sunitinib therapy [3]. In the present analysis, median PFS for sorafenib and sunitinib was 5.8 and 5.7 months, respectively, and these findings based on real-life patients are comparable to the results of the above prospective studies.

In addition to prospective trials, several recent studies based on real-world data have shed light not only on prescription patterns of targeted agents, but also on the outcomes of various sequencing strategies that are difficult if not impossible to evaluate in prospective randomised trials.

Pal et al. studied a cohort of 696 patients treated with everolimus as the second targeted agent, comparing outcomes of patients treated with first-line sunitinib or sorafenib and patients who received pazopanib, a drug with no second-line treatment established based on randomised trials. The outcomes of patients treated with sunitinib or sorafenib and pazopanib were similar [14].

The IMDC have done much to further our understanding of treatment sequencing in mRCC. The IMDC model has been validated for predicting the outcomes of second-line treatment [15].

In a cohort from a community-academic registry of mRCC patients Harrison et al. showed that various sequencing patterns may translate into different outcomes, in particular regarding the first-line therapy with mTORi which was also associated with worse survival in a prospective trial [16, 17].

The results of observational studies investigating the VEGFi-VEGFi versus VEGFi-mTORi sequences are inconclusive due to significant heterogeneity in the observed effect of second-line therapies and potential bias [18‐20]. The only randomised study of second-line therapy directly comparing VEGFi with mTORi is the recently published METEOR trial. In the METEOR trial, PFS was longer with cabozantinib compared to everolimus in patients who had progressed after VEGFi [21]. However, cabozantinib is also a c-Met inhibitor in contrast to other VEGFi such as sunitinib, pazopanib, sorafenib, and axitinib. The results obtained with cabozantinib may not be generalizable to other anti-VEGF agents as c-Met pathway is important in the development of secondary resistance to VEGFi.

Recently, an analysis of the IMDC database suggested that the change in the IMDC prognostic score can be predictive for response to second-line therapies. Patients who had deteriorated from favourable to intermediate prognosis while on first-line VEGFi benefited from switch to mTORi [22].

It remains to be seen whether the issue of VEGFi-mTORi versus VEGFi-VEGFi sequence will become moot with the arrival of agents with different mechanism of action for second-line therapy, in particular nivolumab [23]. The advent of immunotherapy will undoubtedly add new complexities to the discussion of mRCC second line-treatment strategy. First, PFS may not be a meaningful parameter in patients treated with immune checkpoint inhibitors like nivolumab. Moreover, immunotherapy may result in long-term disease control in a substantial proportion of patients, something that is unusual with other targeted agents.

The question whether the efficacy of first-line treatment can be used to guide the selection of the second-line therapy has been studied by several groups in retrospective studies. Al-Marrawi et al. did not detect any association between PFS on the first- and second-line VEGFi [24]. In an earlier study based on RENIS registry we also addressed this issue with similar conclusion for sunitinib-sorafenib or reverse sequences [7]. However, in subsequent analysis we observed an association between PFS on first-line VEGFi with PFS on second-line everolimus, a finding confirmed in the present report on an updated cohort [9]. Recently, Vogelzang et al. compared second-line therapy with everolimus and axitinib. No significant differences were seen in PFS or OS and PFS on first-line anti-VEGF agent was not useful for second-line treatment selection [25]. This topic was recently addressed by several studies that point out that patients primarily refractory to VEGFi will have poor prognosis regardless of second-line strategies [26, 27]. It remains to be determined whether the association observed between PFS on the first or second line therapies reflects susceptibility of the tumour to targeted agents or rather a more indolent course of disease.

The proportion of patients who received second-line treatment (50.6%) in the present study is consistent with most previously published observations, such as the study of Levy et al. (52%) and Beisland et al. (45% of the 2011 cohort) [28, 29]. In the largest, IMDC registry-based study of 2106 patients with the median follow-up of 36 months, 43% received second line therapy [30]. On the other hand, only 15% of patients from the British RECCORD database received second line-therapy [31].

The present retrospective study has several limitations. Pazopanib was not available in the Czech Republic before 2010 and was subject to reimbursement restrictions afterwards. Everolimus was generally not reimbursed when administered after pazopanib until 2014. As a consequence, pazopanib-everolimus sequence was used in only 32 patients in the RENIS database. PFS and OS assessment for axitinib that currently represents a prominent second-line agent was not possible due to the short duration of its use in the Czech Republic, with only 29 patients were included in the database fulfilling the inclusion criteria for the present study. Due to the retrospective character of the present study, there is obviously a risk of selection bias resulting in imbalances between the subgroups and underreporting of adverse events. Moreover, the timing of disease assessment with imaging differed among centres, and there was no central review of the response.

Some trends observed in the present study are best explained by changing availability of reimbursed drugs. No further targeted therapies were reimbursed after everolimus, explaining the lower uptake of third-line treatments in these patients. The decline in utilisation of everolimus in 2012 is likely related to the arrival of pazopanib. According to reimbursement rules at the time, second-line everolimus was not allowed after pazopanib and the patients had to have another line of VEGFRi, mostly sunitinib.

We report here national registry-based data on the efficacy and safety of everolimus, sorafenib, and sunitinib as second-line therapy of mRCC that are comparable with the results of prospective randomized clinical trials. Currently, no single agent can be regarded as unambiguously superior in this setting. International guidelines should be observed and treatment should be selected in conformity to individual patient clinical characteristics.